poisar

Stocks · News reference

Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3

BenzingaBenzinga Newsdesk

Wells Fargo analyst Evan Stampler maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5.5 to $3.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncResearchandmarkets.Com

    Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments

    The global paternity and relationship testing market is expanding beyond traditional paternity testing into broader applications including maternity, grandparent, sibling, and infidelity testing. The market is projected to grow from $1.08 billion in 2025 to $1.45 billion by 2030 at a CAGR of 6.1%. Growth is driven by increased direct-to-consumer genetic testing accessibility, cultural shifts in family definitions, and demand for legally recognized testing. However, the market faces challenges from increased competition, lower pricing, and regulatory complexity across jurisdictions.

  2. Globenewswire IncNa

    Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial

    Myriad Genetics announced the promotion of Vishal Sikri to Executive Vice President - Commercial effective September 16, 2026, replacing departing Chief Commercial Officer Brian Donnelly. Sikri, who previously served as SVP of Product, brings molecular diagnostics and oncology expertise. The company reaffirmed its full-year 2026 financial guidance.

  3. SEC EDGARSEC EDGAR

    8-K filing — MYRIAD GENETICS INC (MYGN)

    Filed: 2026-09-16 AccNo: 0000899923-26-000079 Size: 206 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits